Clinical Trials associated with ABCG2 x chloride channel x SRPK1 x UGT1A1
EUCTR2019-003779-20-DE
/ Unknown statusPhase 2
An?open-label phase II prospective clinical trial to?investigate safety, tolerability, maximum tolerated dose and anti-tumor?effect for SCO-101 in combination with?FOLFIRI?as?a safe and efficient treatment modality?in metastatic or advanced colorectal cancer (mCRC) patients with acquired?FOLFIRI?resistant cancer disease.
An Open-label Phase Ib Prospective Clinical Trial to Investigate Safety, Tolerability and Maximum Tolerated Dose for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
An open-label dose escalating phase Ib study of SCO-101 in combination with gemcitabine and nab-paclitaxel. The primary objectives are to establish the safety profile and the MTD of SCO-101 when combined with gemcitabine and nab-paclitaxel. The starting dose of SCO-101 is 150 mg and the dose may be increased to a maximum of 350 mg.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.